Business
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Extends Collegium’s Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 – – Collegium Raises 2026 Financial Guidance to Reflect Expected Immediate Accretion from Acquisition – – 2026 Total Product Revenues, Net Expected in the Range of $865 to $895 Million and Adjusted EBITDA in the Range of $475 to $500 Million – STOUGHTON, Mass., May 1
About this update from Collegium Pharmaceutical, Inc.
[{"type":"image","alt":"Collegium Pharmaceutical, Inc.","displaySize":"","headline":null,"caption":"Collegium Pharmaceutical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/d00262a0b75d92cc28a42bcc16d20a1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/S5ES9Zc2Z2psQENPovttBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/d00262a0b75d92cc28a42bcc16d20a1a","width":300,"height":100},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/S5ES9Zc2Z2psQENPovttBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/d00262a0b75d92cc28a42bcc16d20a1a","width":300,"height":100}},"lazy":false},{"type":"text","content":"– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio –","length":130,"tagName":"p"},{"type":"text","content":"– Extends Collegium’s Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 –","length":103,"tagName":"p"},{"type":"text","content":"– Collegium Raises 2026 Financial Guidance to Reflect Expected Immediate Accretion from Acquisition –","length":101,"tagName":"p"},{"type":"text","content":"– 2026 Total Product Revenues, Net Expected in the Range of $865 to $895 Million and Adjusted EBITDA in the Range of $475 to $500 Million –","length":139,"tagName":"p"},{"type":"text","content":"STOUGHTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced that it has completed the acquisition of AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years of age and older. Collegium also raised its 2026 financial guidance to include the anticipated impact of the AZSTARYS acquisition.","length":497,"tagName":"p"},{"type":"text","content":"“We are pleased to complete the acquisition of AZSTARYS, a highly strategic addition to our portfolio that strengthens our position in ADHD and further reinforces our long-standing commitment to improving patient care and delivering shareholder value,” said Vikram Karnani, President and Chief Executive Officer. “AZSTARYS is a complementary and diffe...